
SGTX
Healthcare · Biotechnology · $56.2M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2023
EPS trend, 90 days to now · -19.7% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 7, 2023 | Before the open | -4.71 | -3.00 | +36.3% |
| May 9, 2023 | Before the open | -0.23 | -0.23 | 0.0% |
| Mar 14, 2023 | After the close | -0.38 | -0.21 | +44.7% |
| Nov 10, 2022 | Before the open | -0.42 | -0.27 | +35.7% |
| Aug 4, 2022 | After the close | -0.43 | -0.44 | -2.3% |
| May 12, 2022 | After the close | -0.33 | -0.43 | -30.3% |
| Mar 14, 2022 | After the close | -0.56 | -0.55 | +1.8% |
| Nov 10, 2021 | After the close | -0.66 | -0.63 | +4.5% |
| Aug 10, 2021 | Before the open | -0.63 | -0.65 | -3.2% |
| May 10, 2021 | After the close | -0.59 | -0.60 | -1.7% |
| Mar 18, 2021 | After the close | -1.37 | -1.15 | +16.1% |
| Dec 7, 2020 | After the close | 0.00 | -0.45 | — |
| Sep 28, 2020 | Time not confirmed | — | -0.65 |
Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205,…
| — |
| Jun 30, 2020 | Time not confirmed | 0.00 | -2.54 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -2.54 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | -2.81 | — |
| Sep 30, 2019 | Time not confirmed | 0.00 | -2.81 | — |
| Jun 30, 2019 | Time not confirmed | 0.00 | -2.53 | — |
| Mar 31, 2019 | Time not confirmed | 0.00 | -2.53 | — |